# Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)

> **NIH NIH UM1** · EMORY UNIVERSITY · 2022 · $11,669,860

## Abstract

This Infectious Diseases Clinical Research Consortium Leadership Group (IDCRCLG or LG) is a new,
collaborative national partnership of leading infectious diseases, human immunology and clinical research
experts from eight outstanding academic institutions providing experience, guidance, global connectivity and
innovative approaches to address NIH/NIAID clinical research priorities. The emphasis (and strength) of the
IDCRCLG is to facilitate, plan and help implement clinical research for respiratory and enteric infections,
malaria/tropical diseases, and sexually transmitted infections (STIs), and to respond to emerging
infectious diseases (EID). Priority research will include interventional trials and clinical research studies for
vaccines, biologics, therapeutics, diagnostics and devices targeting these infectious diseases. The LG’s
experts and their programs at the eight universities and beyond have a historic record of accomplishment in
vaccine and therapeutic clinical research, and immunologic and pathogenesis studies for these NIAID-priority
infectious diseases. The LG brings extensive expertise with the conduct of Phase I-IV clinical trials including first-
in-human studies, cutting-edge human immunology, pharmacokinetics; engagement with diverse populations
both nationally/internationally, sIRBs, innovative public-private partnerships, and Investigational New Drug
applications (INDs). The group also has strong connectivity to and will leverage NIH/NIAID-supported networks;
extensive experience in collaborating with industry partners and foundations, and leadership of complex
administrative consortia. This cadre of diverse infectious diseases experts proposes to establish and operate
with NIAID and the reconstituted Vaccine and Treatment Evaluation Units (VTEUs), an integrated, highly-
functional, efficient IDCRC to develop innovative scientific and operational strategies in priorities such as
vaccines and STI clinical research. The organizational structure supporting the science and operations of the
IDCRCLG is composed of a Leadership Operations Center including Expert Working Groups, a Clinical
Operations Unit, a Laboratory Operations Unit, and a Statistical and Data Science Unit. Key functions of
the LG are to propose, review and prioritize innovative concepts; to enhance integration and efficiency in
operations; to form collaborative teams; to ensure quality and timely protocol implementation; to disseminate the
results; to promote integration of all populations in IDCRC research across the human lifespan; and to attract,
engage and retain the next generation of scientists in infectious diseases clinical research. In addition, the LG’s
experience with EID threats, links to global partners/sites, access to the highest-level clinical and laboratory
containment facilities and to large populations will help the IDCRC to respond rapidly (surge capacity) during a
public health emergency. The LG’s decades of experience with public health, regu...

## Key facts

- **NIH application ID:** 10469017
- **Project number:** 3UM1AI148684-03S2
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Kathleen Maletic Neuzil
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $11,669,860
- **Award type:** 3
- **Project period:** 2021-08-13 → 2023-05-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10469017

## Citation

> US National Institutes of Health, RePORTER application 10469017, Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) (3UM1AI148684-03S2). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10469017. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*